StemCells Inc. (STEM) Announces Closure Of Enrollment In Phase 1/2 Dry Age-Related Macular Degeneration Trial
6/20/2014 8:25:14 AM
NEWARK, Calif., June 20, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) yesterday announced that based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later this year. Interim results for the current AMD trial show a 70 percent reduction in the rate of geographic atrophy (GA) as compared to the control eye and a 65 percent reduction in the rate of GA as compared to the expected natural history of the disease following a single dose of the Company's proprietary HuCNS-SC® human neural stem cells. In addition to these initial efficacy findings, the Phase I/II trial has also demonstrated a favorable safety profile for HuCNS-SC® as a treatment for dry AMD. Final results from this landmark study are expected to be released mid-2015.
Help employers find you! Check out all the jobs and post your resume.
comments powered by